A 52-year-old nonaddict man in November 2014 presented with complaints of cough and exertional dyspnea for 2 months. On examination, his vital parameters were normal. He had reduced breath sounds over the left basal regions on the respiratory system examination. The other system examinations were normal. Routine investigations showed hemoglobin of 15.3 g/dl, total leukocyte count of 7500/µL, blood sugar level of 89 mg/dl, and urea of 9 mg/dl. The chest radiograph showed left pleural effusion with bilateral nodular opacities [ Figure 1 
INTRODUCTION
Non-small cell lung cancer (NSCLC) accounts for 85% of lung cancers. The prevalence of epidermal growth factor receptor (EGFR) mutations in NSCLC varies from 30% to 40% in Asians. [1] EGFR-tyrosine-kinase inhibitors (TKIs) have been established as a treatment of choice for EGFR mutations. However, resistance develops to EGFR-TKIs in about 60% of cases, commonly due to T790M mutation. [2] Osimertinib/AZD9291 is a third-generation EGFR-TKI approved for use in T790M mutant NSCLC, with an overall response rate of about 60%, but acquired resistance to it occurs in about 10 months. [3, 4] There are various mechanisms of acquired resistance to third-generation TKIs. We report a case of acquired resistance to osimertinib due to C797S mutation. To the best of our knowledge, it is the first case of osimertinib resistance to be reported in an Indian patient. emission tomography (PET) scan [ Figure 3a] and magnetic resonance imaging of the brain done for staging detected distant metastases in the brain and multiple vertebrae. His performance status was Stage 2 and TNM staging was Stage IV. He was started on erlotinib at a dose of 150 mg daily.
He had good therapeutic response but developed acneiform lesions over the face, neck, and upper extremities. On continuing treatment, the rashes resolved. At the end of 6-month treatment with erlotinib, follow-up PET-CT showed partial response as per "response evaluation criteria in solid tumors" with resolution of lung and skeletal lesions, though pleural effusion remained unchanged [ Figures 2b and 3b] . Pleurodesis was done for persistent left pleural effusion using bleomycin. Twelve-month posterlotinib treatment, imaging studies showed progressive disease with increase in lung nodules and new abdominal deposits arousing suspicion of erlotinib resistance [ Figures 2c and 3c ]. Repeat biopsy of the lung lesion detected the presence of T790M mutation in May 2016. He was then started on osimertinib 80 mg once daily. He had good clinical and radiological [20] 69/F USA EGFR L858R mutation Brain radiotherapy, erlotinib 8months 5months Multiple mechanisms including G796S/R mutation 2017 D Zheng et al. [21] 56/F China Chemotherapy, gefitinib 13months 6.5 months G796D mutation Radiotherapy 2016 K Chen et al. [22] 3 patients
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DISCUSSION
The first-generation EGFR-TKIs are recommended as the first-line treatment of advanced NSCLC harboring EGFR-sensitive mutations specifically exon 19 deletions and/or L858R mutation in exon 21. Although both gefitinib and erlotinib have shown similar effectiveness, erlotinib is associated with lower central nervous system recurrence rate compared with gefitinib in patients with brain metastases. [5] Hence, erlotinib was preferred in our patient.
Resistance develops to first-generation EGFR-TKIs after a median of 9-12 months of treatment in majority of the patients. T790M mutation is the most common mechanism occurring in 50%-60% of cases. [2, 6] The second-generation EGFR-TKIs, i.e., afatinib, dacomitinib, and neratinib have demonstrated promising activity against T790M in preclinical models but have failed to overcome resistance in clinical patients due to dose-limiting toxicity. [7] Guidelines have recommended third-generation TKI osimertinib as standard single-drug therapy for patients with metastatic EGFR T790M mutation-positive NSCLC. Osimertinib received its first global approval by the US Food and Drug Administration in November 2015 based on the AURA trials which demonstrated an objective response rate of 61%-66% and a progression-free survival of 9.6-11 months in patients with T790M-positive NSCLC treated with osimertinib. [3, 4, 8] Similar results were found in AURA-3 trial too. [9] Our patient was started on osimertinib in May 2016. However, the patient developed resistance to osimertinib after 20 months.
A liquid biopsy was done for the patient initially. During the last few years, there is growing interest in liquid biopsy to assess the mutational status on circulating tumor DNA. It has a concordance rate of 60%-90% with those of tumor tissue but is limited by the relatively low sensitivity (60%-80%). [2, 10] In clinical practice, liquid biopsy is now recommended as the first choice; the tumor biopsy is recommended only in the case of a negative result. In our case, the liquid biopsy was negative, so repeat tissue biopsy was performed.
The tissue biopsy showed resistance to osimertinib due to C797S mutation. The osimertinib resistance has been reported due to several mechanisms. The mechanisms can be EGFR dependent type or EGFR independent type. The EGFR dependent mechanisms are acquisition of new mutations (like C797S, G796D, G796S/R, L792F/Y/H, or C797G), amplification of exon 19 deletion or loss of T790 M mutation. The various EGFR independent mechanism are alternate kinase activation (MET and HER2), histological transformation, and phenotypic change such as epithelial-mesenchymal transition. [11] There can also be multiple heterogeneous mechanisms in a single patient. We searched PubMed regarding this resistance pattern with search words "osimertinib resistance." It yielded 24 citations for case reports or series. Most of these resistance cases have been described in trial condition. Only 20 clinical cases of acquired resistance to osimertinib have been reported independent of trial, details of which are shown in Table 1 . It shows that majority of the patients are from China. The principle mechanism is EGFR C797S mutation seen in 9 patients, i.e., 45% of cases. Multiple mechanisms were seen in 4 patients. The patients developed resistance after a variable period of 2-18.9 months. [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] Osimertinib acts by covalently binding to the EGFR kinase-binding site C797, and acquired resistance to osimertinib occurs possibly by abolishing the covalent binding between osimertinib and C797 residue which was the mechanism in our case. [11] The patient thus had a triple mutation or "triple whammy" of EGFR exon 19 deletion/T790M/C797S mutations.
The recent National Comprehensive Cancer Network guidelines, version 4.2018, recommend switching over to chemotherapy in case of suspicion of osimertinib resistance, but no drugs have been approved for a specific mutation to date. The C797S mutation can vary in its management based on cis (both in the same allele) or trans (in different allele) association with T790M. If the association is in trans, the combination of first-and third-generation EGFR-TKIs might be helpful, whereas, if the association is in cis, then the patients are resistant to all three generations of EGFR-TKIs. [11] In our patient, it was cis type. The anti-EGFR monoclonal antibodies, such as panitumumab or cetuximab with brigatinib, a dual inhibitor of EGFR and ALK and EAI045, may be effective in our patient apart from chemotherapy. [11] Thus, our patient who had a Stage IV lung cancer survived for 3.5 years and hoping for more with a good quality of life due to proper management with advancement in precision medicine.
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